In regards to Merck, Anyone know Is the below info is coming out soon?
MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells.
In vivo, MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Also in regards to AstraZeneca,
The patented hydrophobic ion pairing approach that BIND developed partially through their collaboration with AstraZeneca demonstrates an important benefit of the collaboration strategy. This new approach expanded the number of payloads that are compatible with the ACCURIN platform and is enabling BIND to explore new applications of ACCURIN technology such as extra-hepatic delivery of oligonucleotide-based therapeutics, targeted antibiotics, and novel immuno-oncology approaches.
The sky is the limit going forward !!
Estimated Enrollment: 72
Study Start Date: October 2015
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Sentiment: Strong Buy
On the horizon is a potential AstraZeneca buyout meaning an investment og $1.49 at the moment could fetch $20 to $30 a share if and when the offer is disclosed on the ongoing talks between BIND and AZ.
I'd think may investors would like to hold 10,000 shares or more at that time.
There is a good article out on stocktwits about this potential.
I will never really understand why people run and gamble at a casino when odds this good sit right here?
Don't know what will happen in the talks but, if BIND breaks over $1.70 again I'm placing my bets that words gotten out the talking has gone well.
For between $500 million and $700 million. For AstraZeneca, the payoff from an acquisition would be mainly technology for making biotechnology drugs, and a particular drug AZD1152 is now in Phase 1 trials, with the first patient enrolled last November.
Talks illustrate how once again the big pharmaceutical companies and the biotechnology industry are increasingly overlapping in the drugs they develop.
Biotech drugs are attractive for the big drug companies because they are becoming more important in treating illnesses like cancer.
AstraZeneca, based in London, already has a collaberation with Bind Therapeutics a deal the companies made in 2013 to work together to develop AZD1152. AstraZeneca's decision to buy all of the smaller company could reflect its satisfaction with the relationship so far.
In addition, AstraZeneca was working non-stop to develop cancer drugs. It is conceivable that the relationship might be endangered now that Bind could get purchase offers from someone else, making AstraZeneca place an even higher value on buying Bind Therapeutics while the cost would berelatively low.
AstraZeneca needs a flurry of drug licensing deals and acquisitions of biotech companies to bolster the company's drug pipeline, which has suffered some setbacks.
AstraZeneca is also facing challenges to the patents protecting some of its best-selling products.
He already is,
Previous efforts with nanotechnology have primarily focused on encapsulating chemotherapy payloads. But the data generated by our collaboration with BIND highlight the ability of ACCURINS®, a polymeric nanoparticle technology, to utilise hydrophobic ion pairing and to improve the therapeutic index of a molecularly targeted anti-cancer drug.
BIND was guilty of success to soon. the horse before the cart. Now things are where they should be and the share price will get back to an ahead of where it once was IMO.
He's a management type at the Hyatt behind the parking garage right next to BIND's Vassar Street location. He was walking back to the parking garage on way back from lunch a street roach coach was providing. He met them at the roach coach and walked back with them.
Only iNSITE 2 trial has done poorly and that's been nown since last year. You need to exercise caution if you've gone short IMO. You could wake up with a much higher value of the stock and if short what would you do?
I can see bashing or reverse pumpomg to try and by cheap and go long. It's just dishonest is all. IMO
Why are you spreading missinformation?
The iNSITE 1 part of the trial went well. Already knew about iNSITE2
“While the single-arm design of these trials precludes definitive conclusions, we remain especially intrigued by the iNSITE 1 data in squamous histology non-small cell lung cancer patients,” said Hagop Youssoufian, M.D., chief medical officer, BIND Therapeutics. “We believe these data provide additional clinical validation that ACCURINS® successfully widen the therapeutic window of conventional docetaxel. Taken together, we believe these data justify further development of BIND-014 in clinical settings where improved safety and tolerability may be valuable to patients.”
I don't know. I left out they told my friend they couldn't talk about anything work related. that's not something that makes sense to me?
My friend works on the opposite side of the street from 325 Vassar St., inCambridge, MA. He knows I'm invested so asked some group of folks where they worked and the said AstraZeneca and said they be around to go out later after work because they started talking sports. Anyway they said they'd be in meeting over at the office building most the week with BIND. Said they were touring the facility that da. Wonder if it means anything?